toxicity was assessed using the spinal cord explant model originally developed by Rothstein et al. 2) As previously reported, six-eight day old Sprague-Dawley rats were decapitated and their lumbar spinal cords were removed under sterile conditions. Then nerve roots and excessive tissues were removed in sterile Gey's balanced salt solution. Spinal cords were sectioned transversely at 350 mm intervals with a tissue chopper (Mickle Laboratory Engineering Co., Ltd., Surrey, U.K.). Sections were quickly transferred to sterile Gey's balanced salt solution containing glucose (6.4 mg/ml) and separated from one another at room temperature. The tissue slices were placed on the surface of 30 mm Millipore Millicell-CM membranes (Bedford, MA, U.S.A.), 5 slices/membrane, and each membrane was then placed in a 33-mm culture well containing 1 ml medium (pH 7.2), which consisted of 50% (v/v) minimal essential medium with 25 mM N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES), 25% (v/v) heat-activated horse serum (56°C for 30 min), and 25% (v/v) Hank's balanced salt solution supplemented with 25.6 mg/ml glucose and 2 mM glutamine. The culture were incubated at 37°C in a humidified atmosphere containing 5% CO 2 . Culture media along with test chemicals were changed biweekly, unless specified otherwise.
Treatment of Spinal Cord Slices Each experiment had five groups: the control group, the THA group, the riluzole treatment group, the SF treatment group and the combination treatment group. Rat lumbar spinal cord explants, after one week in culture, were treated with THA at 100 mM for three weeks in the THA group. Glutamate excitotoxicity was induced by THA treatment and THA is a specific inhibitor of glutamate transporters. The control group of explants was treated with vehicle only. In the SF treatment group, after one week in culture, the explants were pretreated with SF (10 mM and 4 mM) for 48 h and then cotreated with THA at 100mm. In the riluzole treatment group, after one week in culture, the explants were pretreated with riluzole (5 mM and 2 mM) for 48 h and then cotreated with THA at 100 mM. It has previously been demonstrated that dose of 10 mM SF or dose of 5 mM riluzole is effective in preventing motor neuron death optimally. In the combination treatment group, after one week in culture, the explant was pretreated with the combination of SF (10 mM or 4 mM) and riluzole (5 mM or 2 mM) for 48 h and then cotreated with THA, SF, and riluzole for three weeks.
Immunoblotting Analysis Rat spinal cord explants were removed from Millipore membranes at the end of an experimental treatment and processed to prepare whole tissue extracts using tissue extraction reagents kit from Pierce (Rockford, IL, U.S.A.). The samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the resolved proteins were transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were probed with specific primary antibodies overnight at 4°C. After four washes with phosphate buffered saline with 1% Tween 20 (TPBS), the second antibody was incubated with membranes for 1 h at room temperature. Then the bands of interest were detected using an Odyssey Infrared Imaging System (LI-COR, Lincoln, Nebraska). b-Actin was used as a loading control. The usual green or red color of a band was converted to black and white colors for data presentation.
Immunohistochemistry Immunohistochemical staining technique was used to visualize motor neurons in spinal cord slices. The slices were fixed for 30 min with 4% paraformaldehyde at room temperature and rinsed with phosphate buffer (PB). The explants, after being removed from the Millipore membranes, were washed in Tris-buffered saline for 30 min and then treated with 10% horse serum for 1 h at room temperature. The explants were subsequently incubated with an anti-neurofilament antibody (SMI-32) overnight at 4°C, which was followed by three-time washing with TBS-T and incubation with a biotinylated secondary antibody for 1 h. The explants were further washed and then incubated with a horse raddish peroxidase (HRP)-conjugated ABC staining solution (Vector Laboratories, Burlingame, CA, U.S.A.). The explants were finally mounted on glass slides. Motor neurons are those located at ventral horn of the slice, SMI-32 positive and with cell body diameter of Ͼ25 mM.
1)
Flow Cytometry Mitochondrial transmembrane potential (DY m ) was measured using flow cytometry. About thirty spinal cord slices were pooled and processed to prepare single cell suspensions. As previously reported, the tissues were gently rubbed against a steel mesh (74 nm pore size) with an ophthalmological forcep and cells were collected by rinsing the tissues with phosphate buffered saline (PBS). The cell suspensions were filtered through a copper mesh (45 nm pore size) to remove tissue debris and then the suspensions were centrifuged at 800 g for 3 min. To measure the DY m , 1 ml cell suspension was incubated with 26.3 mM rhodamin 123 at room temperature for 25 min. The cells were then washed twice with PBS and were immediately analyzed by flow cytometry to determine fluorescence intensity (excitation/emission wavelengths, 505/534 nm). Rhodamine 123 was readily and selectively sequestered by normal mitochondria (cells showing strong fluorescence) but was removed from the latter when DY m was lost (cells showing diminished fluorescence).
Measurement of LDH, MDA and Glutamate in Culture Medium Levels of LDH, MDA and glutamate were measured in the medium of spinal cord culture. The measurement was performed according to the instruction provided by the manufacturer. LDH activity was measured using an assay kit from Jian Cheng Biological Engineering Institute (Nanjing, China). Briefly, LDH catalyzed the conversion of lactic acid to pyroracemic acid; the latter reacted with 2,4-dinitrophenylhydrazine to form a product that can be measured spectroscopically. MDA concentrations in culture medium were measured using an assay kit from Jian Cheng Biological Engineering Institute (Nanjing, China). MDA is one of the most important degradation products of lipid peroxidation. It can react with thio-barbituric acid to generate mauve material. We can calculate the enzyme activity through shade selection in 532 nm. Glutamate concentrations in culture medium were measured using an assay kit from Jian Cheng Biological Engineering Institute (Nanjing, China). The assay is based on the conversion of glutamate to a-ketoglutarate catalyzed by glutamic dehydrogenase with concomitant conversion of NADϩ to NADH.
Statistical Analysis All values were expressed as meansϮS.D. Results were analyzed using SAS statistical software (version 6.12). Differences between groups were analyzed by one-way analysis of variance (ANOVA). If the F values were significant, Student-Newman-Keuls multiple range test was used to compare multiple groups. Differences are considered significant at pϽ0.05.
RESULTS

Combination of SF with Riluzole at Optimal Doses
Stimulates the Expression of Nrf2, HO-1 and NQO1 at Protein and Reduces Glutamate Accumulation in the Extracellular Space SF can activate the nuclear factor erythroid 2-related factor 2-antioxidant response element (Nrf2-ARE) pathway, whereas riluzole can reduce extracellular acumulation of glutmate by blocking glutamate releasing. The question is whether the combination of the two agents can stimulate the expression of Nrf2 and Nrf2 downstream genes and reduce glutamate accumulation in the extracellular space. At the end of the experimental treatment, the explants are harvested for measurement of expression of Nrf2, reduced nicotinamide adenine dinucleotide phosphate (NADPH): quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1) by immunoblotting analysis. Nrf2 accumulated and the expression of two Phase II enzymes, including HO-1 and NQO1, increased in the SF (10 mM) treatment group and the combination treatment group (Fig. 1) . Interestingly, THA itself also up-regulated HO-1 and NQO1, perhaps resulting from cellular response to glutamate-induced oxidative stress, since oxidative stress may lead to activation of Nrf2-ARE signaling. 19) Riluzole (5 mM) had a negligible impact on the activation of the three proteins.
As expected, treatment of the spinal cord explants with THA (100 mM) elevated medium glutamate level by more than 2 fold, from 14Ϯ2.12 mM in the control to 35.05Ϯ4.21 mM in the THA treatment group (Fig. 2) , which is similar to the previous data. 20) In riluzole treatment group and the combination group, the medium glutamate levels were 23.93Ϯ 5.12 mM, and 25.71Ϯ4.35 mM, respectively. SF at 10 mM had a negligible impact on THA-induced increase in extracellular glutamate and did not alter the effect of riluzole on glutamate. These results clearly indicate that the protective effect of SF against glutamate excitotoxicity does not result from modulation of extracellular glutamate.
Combination of SF with Riluzole at Optimal Doses Protects against Glutamate Excitotoxity-Induced Motor Neuron Death in Spinal Cord Explants
At the end of the experimental treatment, the explants are harvested and stained with an anti-neurofilament antibody (SMI-32) for visualization and counting of motor neurons. There are 17.57Ϯ4.36 motor neurons per ventral horn in the control group, but only 5Ϯ1.21 motor neuron per ventral horn after THA treatment, a 70% decrease (Fig. 3) . This finding is sim- 
. Effect of Combination of SF and Riluzole at Optimal Dose on Extracellular Glutamate Levels
At the end of experimental treatment, the medium was removed for biochemical measurement for glutamate content. Each value marked with an asterisk is different from that in the THA group (pϽ0.01). ilar to that reported previously. 2, 20) In the riluzole treatment group (5 mM) and SF treatment group (10 mM), the number of motor neuron is similar to that in the control group. Obviously, SF or riluzole at these doses alone can protect against glutamate excitotoxity-induced motor neuron death. Interestingly, the number of motor neuron in the combination treatment group remains much higher than that in the THA group, from 18.95Ϯ3.76 to 5Ϯ1.21.
The levels of LDH and MDA in the medium were also measured. At the end of the experimental treatment, the spinal cord explants and the culture media were harvested for measurement of MDA, LDH and mitochondrial transmembrane potential. The LDH level in the control medium was 154.10Ϯ10.21 U/l, but increased to 221.42Ϯ11.01 U/l after THA treatment (Fig. 4A) . In riluzole , SF and the combination treatment groups, the LDH levels (riluzole: 153.24Ϯ 10.02 U/l; SF: 154.97Ϯ9.02 U/l; SFϩriluzole: 153.71Ϯ9.6 U/l) were significantly lower than that in the THA group, and there was no significant difference among the three groups.
The change of MDA level in the medium is similar to that of LDH. The concentration of MDA is 24.67Ϯ2.1 mmol/ml in the vehicle treated explants, but increased to 34.01Ϯ 2.17 mmol/ml after THA treatment. In riluzole, SF and the combination treatment group, the MDA level (riluzole: 24.05Ϯ2.92 mmol/ml; SF: 22.86Ϯ2.54 mmol/ml; SFϩrilu-zole: 23.74Ϯ2.09 mmol/ml) were significantly lower than the THA group and there was no significant difference among the three groups (Fig. 4B) .
The mitochondrial integrity was measured to gain further insight into the neuron-protective activity. Although the assay is not specific for motor neurons and non-neuron cells in spinal cord tissues, THA treatment caused significant loss of mitochondrial trans-membrane potential (DY m ). The riluzole, SF and the combination treatment could fully prevent the loss of DY m (Fig. 4C) .
Combination of SF with Riluzole Is Better Than the Use of a Single Agent at a Low Dose
The main objective of the current study is to investigate whether SF synergizes with riluzole in fighting against excitotoxicity. We used low doses of SF (4 mM) and riluzole (2 mM), each of which alone had little effect on preserving the motor neuron in THAtreated slices, but in combination they showed significant protection against motor neuron degeneration. There were 16.28Ϯ4.23 motor neurons per ventral horn in the control group, but only 4.94Ϯ1.28 motor neurons per ventral horn after THA treatment, a 70% decrease. The number of neurons per ventral horn was 6.78Ϯ2.13 (SF), 6.33Ϯ1.93 (riluzole), and 9.81Ϯ2.85 (SFϩriluzole), respectively (Fig. 5) .
The levels of LDH and MDA in the medium was also measured. The LDH level in the control medium was 154.10Ϯ10.21 U/l, increased to 221.42Ϯ11.01 U/l after THA treatment. In the combination treatment group, the LDH level (183.71Ϯ7.62 U/l) was significantly lower than that in the THA group, the SF group and the riluzole group (Fig.  6A ).
The change in MDA level in the medium was similar to that of LDH. The MDA level in the control medium was 23.57Ϯ2.60 mmol/ml, increased to 34.47Ϯ2.36 mmol/ml after THA treatment, but was 28.72Ϯ1.82 mmol/ml in combination treatment group which was lower than in the THA treatment group. SF or riluzole at low dose alone had a negligible impact on THA-induced increase in extracellular MDA (SF: 32.56Ϯ2.56 mmol/ml; riluzole: 33.43Ϯ2.24 mmol/ml) (Fig. 6B) .
DISCUSSION
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by the progressive and selective death of motor neurons. The cause of this process is mostly unknown, but evidence is available to suggest that excitotoxicity and oxidative stress are important pathogenic factors. 21) Glutamate excitotoxicity can lead to generation of reactive oxygen species (ROS) and mitochondrial damage. 1, 22, 23) Increased ROS is capable of causing considerable oxidative damage to neurons. 24) Oxidative stress may also inhibit glutamate transporter protein GLT-1, leading to extracellular glutamate aggregation. Excitotoxicity and oxidative stress together can aggravate the development of disease.
THA-induced glutamate excitotoxicity in organotypic spinal cord cultures has been one of the widely used models of motor neuron degeneration. This experimental model is characterized by a relatively selective and slow loss of ventral horn motor neurons resulting from glutamate transport inhibition.
2) In our study, treatment of spinal cord slices with THA led to significant increase in glutamate level in the medium, motor neuron death, loss of cell integrity, increased lipid peroxidation and significant loss of mitochondrial transmembrane potential, indicating glutamate excitotoxicity. The results are similar to previously published data. 20) SF is a hydrolysis product of glucoraphanin, the primary glucosinolate present in broccoli. A great deal of recent researches show that SF can exert neuroprotection in ischemia model in vivo and prevent oxidative neuronal death in vitro, [12] [13] [14] by inducing several phase II enzymes. SF can activate nuclear transcription factor Nrf2, which is redox-sensitive and can up-regulate the cellular antioxidant defence mechanisms. Once activated, Nrf2 translocates into nucleus and binds to the antioxidant response element (ARE), which is present in the promoter regions of many antioxidant genes such as NADPH: quinone oxidoreductase (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC) and heme oxygenase-1 (HO-1) . Phase II enzymes perform a variety of vital cellular functions which are important for protecting against oxidative damage. HO-1 is an antioxidant defense enzyme, which can break down free heme to bilirubin, carbon monoxide and iron. HO-1 is highly inducible in most cell types and exhibits potent anti-inflammatory, anti-fibrotic, and anti-apoptotic properties. 25, 26) It has been demonstrated that the induction of HO-1 confers cytoprotection against oxidative tissue injury in many in vitro and in vivo model systems. NQO1 is an obligate two-electron reductase that catalyzes reduction of a broad range of substrates. NQO1 is considered as a detoxification enzyme because of its ability to reduce reactive quinones and quinone-imines to less reactive and less toxic hydroquinones. 27) In our study, Nrf2 accumulated and the expression of two phase II enzymes, including HO-1 and NQO1, increased in the SF (10 mM) treatment group and the combination treatment group (Fig. 1) . Our results also showed that SF exerted efficient protection to motor neurons (Figs. 3, 4) . Some known inducers of Phase II enzymes, including 5,6-dihydrocyclo penta-1,2-dithiole-3-thione (CPDT), were also found to confer protection of spinal cord motor neurons against glutamate-induced excitotoxicity in our previous studies. 20) These results provide further support to the belief that induction of phase II enzymes by Nrf2-ARE signaling is fundamental to the neuroprotective activity of sulforaphane.
Riluzole (2-amino-6-trifluoromethoxy benzothiazole PK 6124, RP 54274) is the only drug proven to slow the disease process in humans and has anti-excitotoxic properties. A growing body of work shows that riluzole, a neuroprotective agent with anti-glutamatergic actions, has neuroprotective properties in some animal models and in cell cultures. 28, 29) The mechanisms by which riluzole is able to prevent neuronal death are not fully understood, but it has been demonstrated that riluzole can reduce glutamate release from nerve terminals in vitro and in vivo. 15, 30) These effects can be attributed, in part, to the capability of riluzole to block neuronal ion channels, including sodium and calcium channels. 31) More recently it is reported that riluzole can reduce the glutamate concentrations by enhancing the activity of the glutamate transporters GLAST, GLT1, and EAAC1. 32) In our study, increased motor neuron survival against glutamate excitotoxicty in riluzole-treated spinal cord explants was accompanied by reduced accumulation of glutamate (Fig. 2) . It is possible that the protective effect of riluzole is related to minimize glutamate's deleterious effects by reducing the glutamate concentration.
Thus, riluzole works through a mechanism different from what is employed by SF. It is conceivable that agents like SF may synergize with riluzole in fighting against excitotoxicity. In our study, the combination treatment at optimal doses protects motor neuron against THA-induced excitotoxicity efficiently, but the protective effect of the combination is not higher than either agent used alone. Why there is no cumulative effect of the combination treatment group at optimal dose? It seems that optimal doses of riluzole alone or SF alone can fully prevent motor neuron damage, so the combination treatment shows no superiority. When used at optimal doses, there was no difference among all the treatment groups and the control group, as measured by the number of motor neuron, medium MDA, and LDH level, and mitochondrial trans-membrane potential (Figs. 3, 4) . To vertify our analysis and inference, we used riluzole or SF at a low dose.
While neither agent at such dose showed protective effect on motor neuron, combination of the two agents at the low doses offered significant protection of motor neuron against THA, accompanied by the decrease in MDA and LDH levels (Figs. 5, 6) . Our collective results demonstrate that the impact of the combination is better than either used individually.
The neuroprotective mechanisms of the combination are likely multiple. At least one of the contributing mechanisms is that combination of SF and riluzole can stimulate the expression of phase II enzymes and reduces glutamate accumulation in the extracellular space. Because SF or riluzole alone can prevent motor neuron damage, the mechanisms of chronic glutamate toxicity are likely multifactorial, involving not only glutamate release, but also oxidative injury. The combination treatment can target two distinct pharamacological pathways simultaneously.
In summary, our study in part indicates that the combination treatment is more effective than each drug used alone. The combination of SF and riluzole in ALS appears to be promising and further study of this regimen seems to be warranted.
